PATENT CLAIM ANALYSIS

Application Number: 15988414
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["514", "045000"]

Abstract:
The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.

Claim (Index 2):
The method according to  claim 1 , wherein the toxicity of said at least one nucleoside analogue is reduced by the at least one second compound which also enhances the antibacterial effect.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 93.0
- Lexical Diversity: 1.9375
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14943555', '10933628', '08460186', '14560097', '14000682']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7163451395290279
- 35 USC 102 Novelty (BERT): 0.510347785054159
- Combined Prediction Score: 0.6957454040815411
- Mean Citation Score: 195.377268
- Max Citation Score: 210.19371
- Similarity Product: 132.07202699484768

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test